Revenue and EBITDA
Tecan delivered CHF 439.5 million in revenue for H1 2025, with an adjusted EBITDA of CHF 65.7 million and an adjusted EBITDA margin of 15%.
Positive Order Entry
Order entry for the first 6 months was CHF 458.3 million, with a sequential improvement in Q2, reflecting mid-single-digit growth in local currencies.
Life Sciences Business Growth
The Life Sciences business returned to growth with a 1.6% increase in local currencies, driven by clinical diagnostics and recovery in consumable sales.
Operational Resilience and Cost Reduction
Tecan realized benefits from cost reduction programs, including a streamlined R&D process in the Cavro business and improved supply chain efficiency.
Innovation Achievements
The company launched new products such as the Veya workstation and Duo Digital Dispenser, receiving strong customer interest and initial orders.
Share Buyback Program
Tecan announced a share buyback program of up to CHF 120 million, reflecting confidence in long-term growth prospects and financial strength.